Five-year experience with incobotulinumtoxinA (Xeomin): the first botulinum toxin drug free of complexing proteins (ENG)

Additional successful clinical use in axillary hyperhidrosis, hemifacial spasm, re-innervation synkinesias and hypersalivation as well as in dystonia and spasticity in extended doses and throughout extended observation periods has been documented meanwhile. Lack of reported cases of antibody-induced therapy failure (ABF), as to date, support the hypothesis of an improved antigenicity.
Автор:  Dressler D.
Год публикации:  2011
Файл:  Загрузить